C-UTS7targeted protein degradation, TRIM21 E3 ligase, aggregate-selective degraders
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Prospectus | 9th TPD & Induced Proximity Skip to content October 26-29, 2026 | Boston, MA About About Event 2025 Speaker Interviews Benedict Cross, Phoremost Ray Deshaies, Amgen/Caltech Nicki Thompson, Trimtech Therapeutics Attendee Stories Protein Degradation Series Hanson Wade What’s On? Full Event Guide Agenda Research Breakthroughs Day Pipeline Progression Day 1 Pipeline Progression Day 2 Future Technologies & Innovations Day Speakers Partner Why Partner Partners Partnership Prospectus Take Part Pricing & Registration Venue & Accommodation Contact Us Full Event Gui
Changing Faces: Board appointments, November and December 2025 | pharmaphorum Skip to main content Saturday 27 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis Deep Dive Research
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
TRIMTECH at Gordon Research Conference on Induced Proximity Modalities | TRIMTECH Therapeutics Limited posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Conti
Neurodegenerative disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcas … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Neurodegenerative disease Neuroscience Lilly bets up to $800M for BioArctic’s brain delivery tech Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain. The pharma hasn’t specified which neurodegenerative disease it will target. June 22, 2026 · 2 min read ·& … apy June 24, 2026 · 4 min read Press Releases X-tosis Receives Grant from The Michael J. Fox Foundation to Advance Novel Parkinson’s Disease Therapy June 23, 2026 · 4 min read Press Releases TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio June 23, 2026 · 1 min read Can-Fite Publishes Peer-Reviewed Scientific … min read Press Releases Oligomerix Awarded $1.9 M NIH Phase II SBIR Fast-Track Grant to Conduct Safety Studies Required for Clinical Studies of OLX-07010 in Alzheimer’s Patients June 17, 2026 · 3 min read Press Releases Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer’s Disease June 16, 2026 · 8 min read Press Releases Coya Therapeutics to Host Virtual W … 2026 · 2 min read Press Releases AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease June 11, 2026 · 5 min read Press Releases Crownlands Releases Largest Open-Source Dataset of Living Patient Cells to Advance AI-Driven Research in Alzheimer’s and Neuroscienc
Alison Lawton appointed as Chair of the Board | TRIMTECH Therapeutics Limited LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agr
Congrats to Prof Will McEwan (UK DRI at Cambridge) who has co-founded a spinout company aiming to develop new small molecule drugs for neurodegenerative conditions👏 TRIMTECH Therapeutics leverages… | UK Dementia Research Institute LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update
TRIMTECH Therapeutics - M Ventures Zum Inhalt springen Wegweiser About Us Portfolio Team Career News Contact Zur Startseite wechseln "> TRIMTECH Therapeutics Novel degraders selective for protein aggregates Trimtech Therapeutics is developing selective small molecule degraders of toxic protein aggregates for treatment of neurodegenerative and peripheral diseases, while leaving functional monomers untouched. The company’s proprietary degrader technology leverages TRIM21 biology as pioneered by the company’s founders Dr Leo James and Dr Will McEwan from the University of Cambridge. Trimtech is h … vestor syndicate, including M Ventures, SV Health Investors’ Dementia Discovery Fund, Cambridge Innovation Capital, Pfizer Ventures, MP Healthcare Venture Management (MPH), Eli Lilly and Company, Cambridge Enterprise Ventures, and Start Codon Hakan Goker Managing Director Legal Information Site Notice / Imprint Terms of Use Privacy Statement © M Ventures, Amsterdam, The Netherlands Social Networks
Women in Leadership: the biotech CEO 11.45am – 12.45pm GMT, 6 March 2025 ‐ 1 hour Panel session Speakers Nara Daubeney Co-founder & CEO, Phaim Pharma Find out more Michelle Teng CEO, Etcembly Ltd Tiffany Thorn CEO, BiVictriX Therapeutics Ltd Find out more Nicki Thompson CEO, TRIMTECH Therapeutics Ltd Find out more Jill Reckless CEO, RxCelerate Find out more × Nara Daubeney Co-founder & CEO, Phaim Pharma Nara is a consultant ENT surgeon at Barts Health NHS Trust with over 10 years of C-suite experience in immunology research and advancing assets through clinical development. She foun
In the News - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu In the News Meet the team: Leo James, Co-founder and Chief Scientific Adviser, TRIMTECH Therapeutics 17 February 2026 – Read news TRIMTECH Therapeutics wins ‘Seed Raise of the Year’ at the 2025 European Lifestars Awards 17 November 2025 – Read news Meet the team: Andrea Testa, Senior Director of Chemistry 05 November 2025 – Read news TRIMTECH Therapeutics wins ‘Start-up of the Year’ at the 2025 TPD & Induced Proximity Awards 17 November 2025 – Rea
Nicki Thompson on #TRIM21's potential for protein diseases | TRIMTECH Therapeutics Limited posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders TRIMTECH Therapeutics: Funding, Team & Investors | Startup Intros Home / Organizations / TRI … MP Healthcare Venture Management , Hakan Goker , M Ventures , Novartis Venture Fund , SV Health Investors Announced Recent News & Mentions Mar 1, 2025 Funding TRIMTECH Therapeutics - Seed Deep Dive High-Level Overview TRIMTECH Therapeutics is a UK-based biotech company developing novel small molecule targeted protein degraders, branded as TRIMTAC™ and TRIMGLUE™ , to selectively eliminate toxic protein aggregates driving neurodegenerative diseases like Alzheimer’s and inf … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with participation from M Ventures, Pfizer Ventures, Eli Lilly, and others; formation of a Scientific Advisory Board (SAB) in September 2025 chaired by Professor Alessio Ciulli; and recognition as one of Fierce Biotech's "Fierce 15" for 2025.[1][2] Origin Story TRIMTECH Therapeutics was incorporated on 21 November 2023 as a private limited company focused on biotechnology R&D (SIC … ealthcare Venture Management, Hakan Goker, M Ventures (Merck), Novartis Venture Fund.
TRIMTECH Therapeutics establishes Scientific Advisory Board | One Nucleus Skip to main content Sign-up Log in Main navigation Events Events Overview ON Helix Genesis Annual Awards Industry Events One Nucleus Events Membership Membership Overview Member Benefits Membership Prices Member Directory Sponsorship Services Services Overview Savings Savings Overview Purchasing Scheme Event Savings Training Training Overview Upcoming Courses Training Sat Nav Mentoring Student & Post Doc Membership Facilities Management Facilities Management Overview Facilities Management Lab Space Equipment for Sal … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther. TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025 the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP
Trimtech Therapeutics Secures $14M in Seed Funding for Neurodegenerative Disease Therapies | AI Tech Supports posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clickin … c , BGF, Cambridge Innovation Capital , SV Health Investors' Dementia Discovery Fund (DDF) ), M Ventures , @Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management Inc , and Cambridge Enterprise Ventures . Led by CEO Dr. Nicki Thompson , Cambridge-based TRIMTECH Therapeutics Limited is developing innovative small molecule targeted protein degraders designed to tackle neurodegenerative and inflammatory diseases. The company's proprietary TRIMTAC platform enabl … ngside Cambridge Innovation Capital and SV Health Investors' Dementia Discovery Fund, Trimtech is aiming to transform the treatment landscape for neurodegenerative disorders. Julia Jones Fractional CFO Alison Lawton Independent Chair Andrea Testa , PhD VP, Chemistry #TrimtechTherapeutics #Biotech #NeurodegenerativeDisease #Alzheimers #DrugDiscovery #LifeSciences #Biotechnology #SeedFunding #HealthcareInnovation #ProteinDegradation #HealthTech #StartupFunding #VentureCapital # … y leading investors including re.Mind Capital, Y Combinator Community , Pioneer Fund, and EvoNexus . 💚CB Therapeutics' innovative solutions in drug development are particularly meaningful to me, as it supports better outcomes for patients while also enabling a more sustainable approach to drug development. This is especially important in a context where healthcare systems are under increasing budgetary pressure, while needs in areas such as neuroscience and mental health con … funding supports autoimmune disease R&D through the Life Science Investment Fund. 🛡️ Emergent BioSolutions Receives $64.5M BAT Contract Modification: Award supports U.S. biodefense preparedness for botulism treatment. 🏥 Inflection Point Healthcare Summit Set for June 4: Baltimore event will explore value-based care, AI, and healthcare deliv
TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board 2 December 2025 Experienced biotech Chair and executive will guide corporate growth and development Cambridge, UK, 2 December 2025: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appoin … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther. TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025, the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, M
Next Generation Degraders and Glues Program About Next Generation Degraders and Glues Online Learning Short Course Speaker Biographies Media Partners Sponsor/Exhibit Sponsorship Opportunities Virtual Sponsorship Opportunities Sponsor/Exhibitor Prospectus Current Sponsors Downloads Travel Hotel and Travel Health and Safety Poster Poster Information Register Next Generation Degraders and Glues Designing Molecular Glues Next-Generation Degraders & Glues Emerging Degrader Modalities and Screening Strategies 20/06/2023 - 22 June 2023 ALL TIMES BST The ubiquitin-proteasome, lysosome and autophag … URED PRESENTATION: Proximity-Based Therapeutics – Where Innovation Meets Application Ryan Potts, PhD, VP and Head, Induced Proximity Platform, Amgen, Inc. , VP and Head , Induced Proximity Platform , Amgen Molecular glues are an exciting opportunity to expand the druggable genome. Here, I’ll introduce the Induced Proximity Platform at Amgen and how we leverage Proximity Biology to discover molecular glues. This will include a discussion of both degrading and non-degr … design of PROTACs and molecular glues. Alternative cereblon warheads and their application in the development of JAK- and LCK- PROTACs with in vivo anti-tumor activity in pediatric ALL models will be described. Development of a large Molecular Glue Library and discovery of GSPT and CK1a degraders with in vivo anti-tumor efficacy will also be disclosed. Panel Moderator: 17:00 PANEL DISCUSSION WITH SESSION SPEAKERS: Targeted Degradation and Tissue-Specificity for Oncology Targ … ations can be achieved through proximity-induction. This talk will focus on the application of the AdPROM system to uncover KLHDC2 as an efficient new degrader of K-RAS, beta-catenin, FoxP3 and STK33 through proximity-induction. The talk will also introduce the newly developed AdPhosphatase system, through which intracellular phospho-proteins can be targeted for dephosphorylation through proximity-induction to rewire cell signalling. 09:35 Degrading Class I Histone Deacetylas … DEGRADER MODALITIES 11:10 Intracellular Antibodies for Biodegraders for PROTAC Application to Transcription Factors from Chromosomal Translocations Terence Rabbitts, FRS, FMedSci, Professor, Molecular Immunology, Center for Cancer Drug Discovery, Institute of Cancer Research , Professor , Molecular Immunology , Institute of Cancer Research Chrom
TRIMTECH Therapeutics establishes Scientific Advisory Board - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu TRIMTECH Therapeutics establishes Scientific Advisory Board 2 September 2025 Targeted protein degradation experts Prof. Alessio Ciulli FRS and Dr Adam Gilbert appointed SAB will provide strategic and scientific perspectives to support development of TRIMTAC and TRIMGLUE selective targeted protein degraders, and small molecule therapeutic pipeline Cambridge, UK, 02 September 2025: TRIMTECH Therapeutics, a … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther. TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025 the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP
TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio | Press Releases | norfolkdailynews.com Skip to main content You have permission to edit this article. Edit Close Log In My Account My Account Dashboard Profile Saved Items Subscribe Manage Service Log Out Subscribe Manage Service Search 72° Home Contact us Advertise Submission forms About Us Where to buy a paper Subscriptions Manage account Epaper Subscribe News Local news State news National news Ag news Business Faith Cou … es Celebrations Anniversaries Birthdays Births Engagements Retirements Weddings Submit an announcement Community Pet Local events Contests Jobs Keeping in touch Legislative updates Weather Cancellations/Delays Local weather Weather cams Print shop Classified sales Browse all Garage sales Auto Employment Real estate Rental Place ad Coupons Newspaper ads Auctions Household Livestock Property Columbus Menu Join Subscribe Donate News Sports Obituaries Opinions Epaper What do you … state batteries (ASSBs) are widely viewed as a safer Youlanda Burnett Announces Award-Winning Short Film Death by Alcohol to Raise Awareness of Addiction Death by Alcohol Reveals the Hidden Effects of Alcoholism, Betrayal, and Women's Health Challenges LOCKPORT, IL, UNITED cjtreeservice.com Enhances User Experience with Major Website Overhaul cjtreeservice.com Completes 1,400-Fix Digital Upgrade to Improve Local Customer Access Caledonia, United States - June Wonder Earns Off
TRIMTECH Therapeutics appoints new Chair of the Board - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies Mi
Novel Drug Modalities | Discovery on Target | Sept 28-Oct 1, 2026 About About The Event FAQ Social Media Wall Agenda Get Involved Programs Search Agenda Downloads In-Person Breakouts Short Courses Plenary Program  Speaker Biographies Training Seminars Attendees Networking Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Current Floor Plan Exhibit Services Schedule Exhibitor Prospectus Lead Generation Opportunities FAQs Sponsor & Exhibitor Portal Best of Show Awards Media Media Partners Newsroom Media Gallery Travel Posters Po … dia Gallery Travel Posters Poster Information Poster Titles Best of Show Poster Award Register Individual Pricing Group Pricing On Demand Pricing Press Novel Drug Modalities Tackling Difficult-to-Drug Targets with Glues, Chimeras, Condensates, Conjugates, Peptides 29 September - October 1, 2026 ALL TIMES EDT The application of innovative design and screening technologies—including artificial intelligence and machine learning (AI/ML)—is rapidly expanding the accessible che … a deep dive into preclinical data from Protai's KAT6 degrader program. 11:35 AM Application of AI and High-Throughput Proteomics for Molecular Glue Discovery Jin Wang, PhD, Director, Biochemistry and Molecular Pharmacology, Baylor College of Medicine , Director , Biochemistry & Molecular Pharmacology , Baylor College of Medicine We will discuss how we apply state-of-the-art high-throughput proteomics to discover molecular glue hits and apply AlphaFold 3-like folding softw … scovery that does not require the synthesis of extremely large libraries and an application of this technology to the creation of phosphatase recruiting chimeras (PHORCs) that engage the PTP1B phosphatase. 2:50 PM Industrializing Molecular Glue Discovery Amine Sadok, PhD, Senior Director & Head of Induced Proximity Platform, Amgen Inc. , Senior Director & Head , Induced Proximity Platform , Amgen Inc. We are industrializing molecular glue discovery to drug previously … s, connect with peers, and turn in your Game Cards for a chance to win a raffle prize. VC Panel INSIGHTS FROM VENTURE CAPITALISTS Panel Moderator: 4:50 PM PLENARY PANEL DISCUSSION: Venture-Capitalist Insights on Trends in Drug Discovery Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation , Chief Innovation Officer ,
Meet the team: Andrea Testa, Senior Director of Chemistry - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu Meet the team: Andrea Testa, Senior Director of Chemistry 5 November 2025 Could you tell us more about your academic and industry journey? What led you to pursue your postdoctoral research with Prof. Alessio Ciulli, co-founding Amphista Therapeutics, and how that path brought you to TRIMTECH as Senior Director of Chemistry. I joined Alessio’s research group over a decade ago, driven by an interest in develo … function. Following TRIMTECH’s launch, you were named a runner-up for the EFMC Prize for a Young Medicinal Chemist in Industry. What does this recognition mean to you? This nomination meant a lot to me, as my path has been very different from that of most medicinal chemists in the industry. While most medicinal chemists develop in large or medium-size pharma which provide structured career ladders and extensive support infrastructure, I started my journey in chemical biology
INNOPOLIS Jeonbuk Sponsors RESI San Diego 2026 | Life Science Nation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board - SV Health Investors Strategy Therapeutics Healthcare Growth Medtech People Portfolio News Contact Investors SV8 Biotech Fund SV7+ Growth Fund Dementia Discovery Fund-2 SV Biotech Crossover Opportunities Fund SV7 Impact Medicine Fund SV7 Growth Fund Dementia Discovery Fund-1 SV Life Sciences Funds 5-6 SV Fund IV Continuation Fund SV Life Sciences Funds 3-4 TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board 2nd December 2025 Experienced biotech Chair and executive will guide corporate growth and development Camb … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther. TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025, the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, M
Speaker Interviews - 9th TPD & Induced Proximity Summit Skip to content October 26-29, 2026 | Boston, MA About About Event 2025 Speaker Interviews Benedict Cross, Phoremost Ray Deshaies, Amgen/Caltech Nicki Thompson, Trimtech Therapeutics Attendee Stories Protein Degradation Series Hanson Wade What’s On? Full Event Guide Agenda Research Breakthroughs Day Pipeline Progression Day 1 Pipeline Progression Day 2 Future Technologies & Innovations Day Speakers Partner Why Partner Partners Partnership Prospectus Take Part Pricing & Registration Venue & Accommodation Contact Us
Nicki Thompson - ABI Conference Skip to content ABOUT Accelerating Bio-Innovation Royalty Pharma SPEAKERS AGENDA PAST ABIs 2026 2025 2024 2023 2022 2019 ABI Sweden AGENDA LOCATIONS ABOUT SPEAKERS --> Registration --> Nicki Thompson Chief Executive Officer TRIMTECH Therapeutics Nicki has over 25 years’ experience in pharmaceutical and biotechnology R&D in a variety of senior scientific and commercial leadership roles. She is CEO of Cambridge-based TRIMTECH Therapeutics (an MRC LMB/UK DRI spin-out), which focuses on a novel targeted protein degradation (TPD) approach to treat neurodegenerati
Nicki Thompson - 9th TPD & Induced Proximity Summit Skip to content October 26-29, 2026 | Boston, MA About About Event 2025 Speaker Interviews Benedict Cross, Phoremost Ray Deshaies, Amgen/Caltech Nicki Thompson, Trimtech Therapeutics Attendee Stories Protein Degradation Series Hanson Wade What’s On? Full Event Guide Agenda Research Breakthroughs Day Pipeline Progression Day 1 Pipeline Progression Day 2 Future Technologies & Innovations Day Speakers Partner Why Partner Partners Partnership Prospectus Take Part Pricing & Registration Venue & Accommodation Contact Us Ful
trimtech therapeutics - Oncology & Immunology Innovation Partnering Skip to content September 9-10, 2026 | Boston, MA About About Event Who Attends Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Day One Day Two One-to-One Partnering Partnering Portal Sponsor Why Sponsor Media Partners Take Part Register Venue & Accommodation Contact Us Event Guide Register About About Event Who Attends Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Day One Day Two One-to-One Partnering Partnering Portal Sponsor Why Sponsor Media Partners Take Part Regist
TRIMTECH Therapeutics appoints Dr Mike Hutton to Scientific Advisory Board - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu TRIMTECH Therapeutics appoints Dr Mike Hutton to Scientific Advisory Board 11 November 2025 Industry leader brings deep expertise across neurodegenerative disease therapeutics development Dr Hutton joins Prof. Alessio Ciulli FRS and Dr Adam Gilbert on SAB Cambridge, UK, 11 November 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively de … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther. TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025 the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP
%PDF-1.7 3 0 obj > /Resources 2 0 R /Contents 4 0 R>> endobj 4 0 obj > stream x��]�vں}�W��3�1�j��9�4�\R ����(�n��1i�7�w�_ �6Ĺ�$�!�� J*6��\KS��P�a�P���I�L����(0=8��c X�e]�7:P�]�L� �6����s�#OX�Rl�5_�ߺ��1T�{�6-(�� �C=_m�ly�4S�C���k ��i�/�k�+Iϒc� Mw�̽�?���+���j�]�KS���!e���~g�%Y卺{m���ͳ��r-Z�^� i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i���# i����ǔ[#���͙����1�j#CaG7;ҔMy�-+����͛❣����c~ߪ&;�|gǔ?�]�c�i�yÎf�x5���,��$1� ��,�;� 7*s�]��t4d>���zj�v*���l���t��I9B��
GAP funding de-risks innovation, attracts downstream capital | Jacob Johnson posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo … c , BGF, Cambridge Innovation Capital , SV Health Investors' Dementia Discovery Fund (DDF) ), M Ventures , @Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management Inc , and Cambridge Enterprise Ventures . Led by CEO Dr. Nicki Thompson , Cambridge-based TRIMTECH Therapeutics Limited is developing innovative small molecule targeted protein degraders designed to tackle neurodegenerative and inflammatory diseases. The company's proprietary TRIMTAC platform enabl … ngside Cambridge Innovation Capital and SV Health Investors' Dementia Discovery Fund, Trimtech is aiming to transform the treatment landscape for neurodegenerative disorders. Julia Jones Fractional CFO Alison Lawton Independent Chair Andrea Testa , PhD VP, Chemistry #TrimtechTherapeutics #Biotech #NeurodegenerativeDisease #Alzheimers #DrugDiscovery #LifeSciences #Biotechnology #SeedFunding #HealthcareInnovation #ProteinDegradation #HealthTech #StartupFunding #VentureCapital # … rket-oriented innovation, 🤝 international R&D collaboration, 🏭 industrial application, 💡 technology commercialisation, 🌍 cross-border biotech ecosystems. 📌 Key Focus Areas: 🔹 Advanced Biomanufacturing & Ecosystem Enablers 🔹 Next-Generation Therapeutics & Treatment Modalities 🔹 Agricultural & Veterinary Biotechnology 🔹 Advanced Diagnostics & Data Technologies 🔹 AI & Bioinformatics Applications 🔹 Biotechnology-driven Sustainable Solutions The … Sweden, Switzerland, Türkiye and additional participating countries. 📌 Who Can Apply? 🏢 SMEs 🚀 Startups 🏭 Large Companies 🎓 Universities 🔬 Research Institutes 🏥 Research Hospitals 🌱 Biotechnology Innovators To be eligible, projects must be developed through an international consortium involving partners from at least two participating cou
Degraders and Molecular Glues - Part 1 | Discovery on Target | Sept 22 - 25, 2025 About About The Event FAQ Social Media Wall Agenda Get Involved Programs Search Agenda Downloads In-Person Breakouts Short Courses Plenary Program  Speaker Biographies Training Seminars Attendees Networking Archives Sponsor/Exhibitor Attendee Demographics + Event Features Sponsorship Opportunities Current Sponsors Current Floor Plan Exhibit Services Schedule Exhibitor Prospectus Lead Generation Opportunities FAQs Sponsor & Exhibitor Portal Best of Show Awards Media Media Partners Newsroom Media Gallery T … dia Gallery Travel Posters Poster Information Poster Titles Best of Show Poster Award Register Individual Pricing Group Pricing On Demand Pricing Press Degraders & Molecular Glues – Part 1 Part 1: Design and Optimization of Novel Degraders, Glues, and Conjugates 9/23/2025 - September 24, 2025 ALL TIMES EDT Hetero bifunctional molecules like proteolysis-targeting chimeras (PROTACs), monovalent molecules like molecular glues, and other novel conjugates and modalities … , Medicinal Chemistry & Induced Proximity , A Alpha Bio Inc We describe the application of AlphaSeq, a high-throughput, highly sensitive experimental platform for measuring protein-protein interactions, to elucidate >100 novel interactions between therapeutically relevant targets and diverse set of ligases. We further characterize these PPIs through site-directed mutagenesis to prioritize actionable pairs for rational molecular glue discovery. Finally, we depict the sy … ss of designing a selection to inform desired PPI mechanisms of action, and the application of this technology to two case studies including a stabilizer of the eIF2B/(p)eIF2a complex. 12:40 PM Session Break NOVEL DEGRADER MODALITIES 1:15 PM Chairperson's Remarks Jin Wang, PhD, Director, Biochemistry and Molecular Pharmacology, Baylor College of Medicine , Director , Biochemistry & Molecular Pharmacology , Baylor College of Medicine 1:20 PM Leveraging High-Throughput … with industry-leading service providers, fill out the Game Card to win a raffle prize and vote for the People’s Choice Best of Show Exhibitor. Plenary Keynote Session Block PLENARY KEYNOTE PROGRAM 10:50 AM Welcome Remarks from Tanuja Koppal, PhD, Discovery on Target Team Lead Tanuja Koppal, PhD, Senior Conference Director, Cambridge Healthtech
UK firm Trimtech emerges with $31M seed round for TRIM21 bispecifics | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 la
#jpm #jpm2026 #biotech #tpd #neurodegeneration | TRIMTECH Therapeutics Limited LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Ag
J.P. Morgan Healthcare Conference - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu J.P. Morgan Healthcare Conference 16 January 2026 J.P. Morgan Healthcare Conference 12 – 16 January 2026 San Francisco https://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svg 0 0 LMason https://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svg LMason 2026-01-16 23:59:16 2025-12-04 13:48:42 J.P. Morgan Healthcare Conference © TRIMTECH Therapeutics TRIMTAC, TRIMVEC and
Events - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu Events Upcoming events Alzheimer’s Association International Conference 2026 12 – 15 July 2026 London, UK Oncology & Immunology Innovation Partnering & Licensing Summit 9 -10 September 2026 Boston Discovery on Target 28 Sept – 1 Oct 2026 Boston Previous events Gordon Research Conference Induced Proximity Modalities & Therapeutics 21 – 26 June 2026 Maine, US Anglonordic Life Science Conference XXII 23 April 2026 London, UK
TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025 - M Ventures Zum Inhalt springen Wegweiser About Us Portfolio Team Career News Contact Zur Startseite wechseln Trimtech Therapeutics TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025 2025/09/22 Fierce 15 highlights pre-commercial biotech companies driving the next generation of therapies for patients worldwide Cambridge, UK, 22 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates to co … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with participation from Pfizer Ventures, M-Ventures, Eli Lilly, and MPH. The team was later delighted when co-founder Dr Leo James was elected as a Fellow of the Royal Society (FRS), one of the highest honours for a UK scientist. In September the Company announced the first two members of its Scientific Advisory Board, prominent targeted protein degradation experts Prof. Alessio Ciulli … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther. TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025 the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP
TRIMTECH Therapeutics Appoints Alison Lawton as Chair | SV Health Investors posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … apeutics Limited , a company created by SV Health Investors' Dementia Discovery Fund (DDF) , has announced the appointment of Alison Lawton as Chair who brings a wealth of expertise in operations, drug development and strategic leadership to guide and support TRIMTECH’s next stage of growth. TRIMTECH Therapeutics Limited 4,240 followers 6mo Delighted to welcome highly accomplished biotech executive Alison Lawton as Chair of our Board of Directors. With more than 35 years of g … eovian has now closed a $55M Series B, backed by Luma Group , CTI Life Sciences Fund , Foresite Capital , SymBiosis , TSC Alliance , and existing investors venBio , Sofinnova Investments , Hevolution Foundation , and Apollo Health Ventures , to advance a first-in-class selective mTOR inhibitor currently in development for TSC-related epilepsy, with much broader implications for aging and age-related disease. Proud of the progress, and humbled to have been part of this journey … uroinflammatory diseases. The Series B includes new investors CTI Life Sciences Fund , Luma Group , Foresite Capital , and SymBiosis , who join Aeovian’s existing investor base in supporting the company’s next phase of clinical development. Apollo Health Ventures , which led the Seed round and subsequently formed the Series A syndicate alongside venBio , Sofinnova Investments , and Hevolution Foundation , remains a committed partner as Aeovian advances one of the most compell … uroinflammatory diseases. The Series B includes new investors CTI Life Sciences Fund , Luma Group , Foresite Capital , and SymBiosis , who join Aeovian’s existing investor base in supporting the company’s next phase of clinical development. Apollo Health Ventures , which led the Seed round and subsequently formed the Series A syndicate alongside
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases March 6, 2025 | 3 min read Twitter LinkedIn Facebook Email Print Oversubscribed financing led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discov … led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund with M Ventures and Pfizer Ventures joining Investment will support further development of CNS penetrant therapeutics based on the Company’s TRIMTAC ™ aggregate-selective degraders CAMBRIDGE, England--(BUSINESS WIRE)--TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 mi … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. The investment will support further development of the Company’s growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules k … e pipeline. ” Laurence Barker, Partner, SV Health Investors’ Dementia Discovery Fund, said: “ The team at DDF is thrilled to co-lead the creation of TRIMTECH to advance its TRIMTAC platform, which harnesses TRIM21’s unique ability to degrade aggregated proteins while preserving functional monomers. While targeted protein degradation has revolutio
TRIMTECH Therapeutics establishes Scientific Advisory Board - PMLiVE Advertise Subscribe Contact Publications PME PME supplements Communique T40 Follow Follow Follow Follow News Research Sales Regulatory Healthcare Marketing Intelligence Intelligence Webinars Podcasts Digital Handbook Orphan drugs & rare diseases Glossary Healthcare Advertising Gallery Thought Leadership Appointments Awards Blogs Digital intelligence Smart Thinking Darwin’s Medicine Webinars T40 Top 40 overall Smaller agencies Independent agencies Young agencies UK focused agencies About T40 Top Pharma list PMHub Company
TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intellig … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board
RSC-BMCS/SCI Targeted Protein Degradation 2026 - RSC BMCS --> Home About Us Committee News Events 9th RSC-CICAG / RSC-BMCS Artificial Intelligence in Chemistry RSC-BMCS 10th Fragment-based Drug Discovery 10th RSC-BMCS/RSC-SCI GPCRs in Medicinal Chemistry RSC-BMCS/SCI Targeted Protein Degradation 2026 BMCS Hot Topics: AI in Drug Discovery 2026 BMCS Antibody-Drug Conjugates 2026 20th Postgraduate Symposium BMCS New Approaches to Neurodegenerative Diseases 9th RSC/SCI Ion Channels as Therapeutic Targets 11th RSC-BMCS Symposium on Mastering Medicinal Chemistry BMCS Event archive Event archive from … e Awards BMCS Hall of Fame and Medal BMCS Lectureship Malcolm Campbell Memorial Prize Capps Green Zomaya Award Grants Bursaries International Travel Prize Researcher Mobility Fellowship Education Support Enhanced Equipment Chemistry Clubs Partnership of 3 Undergraduate Chemical Societies Funding from RSC Local Sections Contact Us Home About Us Committee News Events 9th RSC-CICAG / RSC-BMCS Artificial Intelligence in Chemistry RSC-BMCS 10th Fragment-based Drug Discovery 10th R … e Awards BMCS Hall of Fame and Medal BMCS Lectureship Malcolm Campbell Memorial Prize Capps Green Zomaya Award Grants Bursaries International Travel Prize Researcher Mobility Fellowship Education Support Enhanced Equipment Chemistry Clubs Partnership of 3 Undergraduate Chemical Societies Funding from RSC Local Sections Contact Us Events RSC-BMCS/SCI Targeted Protein Degradation 2026 Charlotte Turpin 2026-06-16T15:17:37+00:00 RSC-BMCS/SCI Targeted Protein Degradation 5 Event R … der Centre, Hatfield Important links Social media hashtag – #ProtDeg26 To submit your Abstract, click here To register, click here To Sponsor, click here To apply for a BMCS Bursary please click here To apply for a SCI Bursary please click here Synopsis One of the most exciting new therapeutic modalities to emerge in the 21st century has been Targeted Protein Degradation (TPD). The targeted protein degradation (TPD) market in 2025 is estimated to be worth between approx … rofit institutions. Preference will be given to members of the RSC-BMCS or SCI. Bursary applications are also invited from RSC or EFMC members who are of working age, but currently unemployed and from those who may have difficulty in funding their attendance. The deadline for applications is Monday 17th August, 2026. To apply for a BMCS Bursary p
Start-up harnesses protein degradation for neurodegeneration - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibo … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. Diana Spencer, Senior Digital Content Editor, DDW Related articles Podcast: Where are scientists making waves in drug discovery? 24 April 2025 • Megan Thomas Resources Webinars Webinar – Towar
Great to see two of our awesome clients on the bill at BioIndustry Association (BIA) Women in Biotech! Michelle Teng and Tiffany Thorn are amazing leaders and we're proud to support their work 🥰 | Kat Arney LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any
New funding takes Trimtech Therapeutics’ seed round to £35.6m - UKTN × Register for Free Bookmark your favorite posts, get daily updates, and enjoy an ad-reduced experience. Register Already have an account? Log in Skip to content Subscribe News Insights Insights Interviews Opinion Analysis Tech Hubs Tech Hubs London North East West Midlands Wales South East North West East Midlands Scotland South West East of England Yorkshire & Humber Northern Ireland Reports Podcast Events Jobs Login Log in Subscribe Login to remove this ad Biotech New funding takes Trimtech Therapeutics’ seed rou
Cambridge’s TRIMTECH Therapeutics brings Seed round to €41 million for neurodegenerative disease work | EU-Startups Sign in Magazine Interviews Re-/Launch Funding Acquisitions Other Stuff Know-How Summit Event Overview Agenda Get Tickets Job Board Job Board Post a Job Insights Startup Sourcing Premium Reports Podcast Database Startup Database Investor Database About us Mission / Team Advertising Our Newsletter – CLUB – Register Now Log In CLUB Benefits Sign in Welcome! Log into your account your username your password Forgot your password? Password recovery Recover your password yo … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr. Damian Crowther. Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, the company has reportedly demonstrated its ‘TRIMTAC’ and ‘TRIMGLUE’ degraders can recapitulate degradation seen with other modalities (vectors and antibodies) whilst leaving the functional monomeric fo … 2026 France-Startups Paris-based Newfund closes €60 million HEKA, a specialist fund for BrainTech April 14, 2026 Austria-Startups Amid €65 billion lost each year to stroke and dementia in Germany, nyra health secures €20 million to scale digital neurotherapy February 24, 2026 Ireland Startups Ireland’s newest pot of gold: 10 of the most promising startups to watch in 2026 February 16, 2026 Funding Irish BioTech startup Aerska raises €32 million to “enable our loved one
AI-optimised plants drug chemistry lands £2.9M. Accession’s viral gene therapy secures £30.5M. UK wins 0% US tariff status for medicines. Subscribe Sign in AI-optimised plants drug chemistry lands £2.9M. Accession’s viral gene therapy secures £30.5M. UK wins 0% US tariff status for medicines. #54 | 8 December 2025 Emily Brown and Andrea Martos Esteban Dec 08, 2025 Share This is Cambridge Biocapital’s newsletter the independent weekly bulletin covering business, funding and science news in the world-leading 🇬🇧British 🧬biotech & 🚀venture capital ecosystem. The Spin Welcome to Issue 54 . … rigid Bio taking home £150,000 . Meanwhile, Mercia Ventures has launched a £35m fund in Newcastle and has already been inundated with 50 applications. On the policy front , a landmark UK-US deal has secured 0% tariffs on Pharma exports, protecting over £5bn in trade. Sir Patrick, upwards and onwards. The government is also increasing medicines spend by ~25% , allowing NICE to raise cost-effectiveness thresholds to £25k–£35k per QALY. Gosh , they like an acronym, don’t they? Q … Research Horizons The round, co-led by Kurma Partners and Curie Capital , will fund progression of Laigo’s oncology SureTAC™ candidates toward clinical development and accelerate three immunology programmes targeting autoimmune disease and graft rejection. Laigo Bio also appointed Dr Matthew Baker as CEO; the company’s SureTAC™ bispecific degraders target membrane proteins long considered “undruggable,” including PD-L1, VEGF and Wnt-pathway receptors. 💸 Norwich-based HotHou … UKI2S , Twin Path Ventures , Wren Capital , angel investors, and an Innovate UK grant, supporting HotHouse’s platform designed to generate sustainable, scalable plant-derived pharmaceutical compounds — including engineered alternatives to the vaccine adjuvant QS-21 . HotHouse Therapeutics uses an AI-driven plant expression system to rapidly produce natural and novel small molecules, with an initial commercial focus on next-generation saponin-based adjuvants such as QS-21 , QS … of Concept , Wellcome Trust Access to Expertise , and the Technology Investment Fund (Cambridge Enterprise) . Gastrobody’s engineered “Gastrobodies” are antibody mimetics built from a soybean-derived protein scaffold, designed to remain stable in the GI tract and capable of being tailored to bind diverse targets. Investment Funds & Accelerato
LMB spinout TRIMTECH Therapeutics will develop targeted protein degraders to treat neurodegenerative conditions | MRC Laboratory of Molecular Biology Skip to content LMB Intranet Science Research Leaders Divisions Facilities Animal Research Training Seminars LMB Developed Software Published Research Careers & People Current Vacancies PhD Students Postdocs Group Leaders Technical & Operational Roles Student Placements Work Experience Employee Benefits LMB Life Equality, Diversity & Inclusion Alumni News & Events Latest News Seminars & Events Public Engagement LMB in t … es About Leadership History Archive Contact Directory How to Find Us Max Perutz Fund Search LMB / News & Events / LMB spinout TRIMTECH Therapeutics will develop targeted protein degraders to treat neurodegenerative conditions Published 26/03/2025 LMB spinout TRIMTECH Therapeutics will develop targeted protein degraders to treat neurodegenerative conditions Leo James co-founds new UK biotech company with Will McEwan (UK Dementia Research Institute at the University of Camb … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF). Damian Crowther, joint entrepreneur-in-residence at CIC and DDF, who cofounded TRIMTECH together with academic co-founders Leo and Will, is now Head of Research, and Nicki Thompson joined as CEO in January 2024. Dean Clift and Jonathan Benn, previously postdocs in the respective academic labs, have joined to accelerate translation into the company. TRIMTECH is based in the Milner Thera
TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board - PMLiVE Advertise Subscribe Contact Publications PME PME supplements Communique T40 Follow Follow Follow Follow News Research Sales Regulatory Healthcare Marketing Intelligence Intelligence Webinars Podcasts Digital Handbook Orphan drugs & rare diseases Glossary Healthcare Advertising Gallery Thought Leadership Appointments Awards Blogs Digital intelligence Smart Thinking Darwin’s Medicine Webinars T40 Top 40 overall Smaller agencies Independent agencies Young agencies UK focused agencies About T40 Top Pharma list PMHub C
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
TRIMTECH Therapeutics raises $31 million seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women i … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources TRIMTECH Therapeutics raises $31 million seed funding to advance targeted protein degradati … idge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. The investment will support further development of the Company’s growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molec … peline. Laurence Barker, Partner, SV Health Investors’ Dementia Discovery Fund, said: The team at DDF is thrilled to co-lead the creation of TRIMTECH to advance its TRIMTAC platform, which harnesses TRIM21’s unique ability to degrade aggregated proteins while preserving functional monomers. While targeted protein degradation has revol
TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Dr … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases TRIMTECH Therapeutics Brings Total Seed Round to $47M with Additional Investment of $14M to Further Develop TRIMTAC and TRIMGLUE Targeted Protein Degradation Portfolio June 23, 2026 | 1 min read Twitter LinkedIn Facebook Email Print Johnson & Johnson’s corporate venture capital organization, Johnson & … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Science - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu Science At TRIMTECH we are developing a unique pipeline of protein aggregate selective degraders known as TRIMTAC ® and TRIMGLUE ® for the treatment of severe neurodegenerative and inflammatory diseases. Our unique approach directs the innate properties of TRIM21, a novel E3 ligase that is expressed in most tissues, to potently and selectively degrade disease-causing protein aggregates, while preserving healthy native versions of these proteins to maintain
Research Scientist - Molecular Cell Biology | One Nucleus Skip to main content Sign-up Log in Main navigation Events Events Overview ON Helix Genesis Annual Awards Industry Events One Nucleus Events Membership Membership Overview Member Benefits Membership Prices Member Directory Sponsorship Services Services Overview Savings Savings Overview Purchasing Scheme Event Savings Training Training Overview Upcoming Courses Training Sat Nav Mentoring Student & Post Doc Membership Facilities Management Facilities Management Overview Facilities Management Lab Space Equipment for Sale About Company … o make a significant impact in the field of drug discovery, we encourage you to apply to join our dynamic team at TRIMTECH therapeutics. You will be a key contributor to the development of groundbreaking treatments for neurodegenerative diseases. Specification Qualifications, Knowledge, and Experience Possess a BTEC, BSc, MSc, or PhD or comparable experience. At least 5 years in an industrial setting, ideally within a CRO, biotech. Hands on experience with high-throughpu … and their role in disease. Understanding of neurodegenerative disease biology. Application Instructions: To apply please send a cover letter and CV to [email protected] Application Closing Date: 13 January 2025 Salary: Competitive salary and benefits package, related to experience & qualifications Why Join One Nucleus? Join One Nucleus, the not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge, for a wide range
LMB spin-out, Heptares Therapeutics, acquired by Sosei Group | MRC Laboratory of Molecular Biology Skip to content LMB Intranet Science Research Leaders Divisions Facilities Animal Research Training Seminars LMB Developed Software Published Research Careers & People Current Vacancies PhD Students Postdocs Group Leaders Technical & Operational Roles Student Placements Work Experience Employee Benefits LMB Life Equality, Diversity & Inclusion Alumni News & Events Latest News Seminars & Events Public Engagement LMB in the News Alumni News Achievements Awards & Prize … es About Leadership History Archive Contact Directory How to Find Us Max Perutz Fund Search LMB / News & Events / LMB spin-out, Heptares Therapeutics, acquired by Sosei Group Published 23/02/2015 LMB spin-out, Heptares Therapeutics, acquired by Sosei Group Structure of the thermostabilised adenosine A 2A receptor (PDB code 3UZC) bound to a lead compound for the treatment of Parkinson’s disease developed at Hepatares Leading Japanese biopharmaceutical company, Sosei Group
Science - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu Science At TRIMTECH we are developing a unique pipeline of protein aggregate selective degraders known as TRIMTAC ® and TRIMGLUE ® for the treatment of severe neurodegenerative and inflammatory diseases. Our unique approach directs the innate properties of TRIM21, a novel E3 ligase that is expressed in most tissues, to potently and selectively degrade disease-causing protein aggregates, while preserving healthy native versions of these proteins to maintain
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
BioMed Realty and Babraham Research Campus Ltd Complete Lease-Up of Newest Building at Babraham Research Campus, with TRIMTECH Therapeutics and Tagomics Submit a Release Home All ESG Health Technology Finance Contributors Sub Menu Submit a Release main-search-pop Main menu BioMed Realty and Babraham Research Campus Ltd Complete Lease-Up of Newest Building at Babraham Research Campus, with TRIMTECH Therapeutics and Tagomics Contributed by: Business Wire Logo Images Tags Science Commercial Building & Real Estate Software Construction & Property Biotechnology Research Health Technology Ba … e All ESG Health Technology Finance Contributors Press Release Hub Our Services Submit a Release Websites PA Media Group PA Mediapoint Distribution Packages © PA Media Group. 2026 Terms of Use Privacy Policy Contact Us
Dark Blue Therapeutics acquired by Amgen for up to $840 million | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Developing your company Protecting your company BioStart: for early-stage … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources Dark Blue Therapeutics acquired by Amgen for up to $840 million Member news 7 January 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
If you haven't already, read the full report here: https://lnkd.in/e2AxatQ8 | TRIMTECH Therapeutics Limited LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in
Trimtech Therapeutics–SEVERAL: investment, 202503 seed financing round £25m led by Cambridge Innovationn Capital + DDF - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) Merck Announces Healthcare Leadership Changes RQ Biotechnology Closes $115m (£85.5m) Series A Financing Tecan Integrates Nvidia’s Agentic AI into Lab Platform Nvidia Announces BioNeMo Agent Toolkit at BIO 2026 Merck Partners with Versant Ventures to Launch Saturnus Bio … rapeutics Raises $5m Investment Led by Daphni Kos Biotechnology Partners: First Fund Reaches $123m Caszyme: WiFIX Consortium Awarded €1m Eurostars Grant AMD, Dell & Univ Cambridge Launch UK AI Innovation Lab GSK to Acquire Nuvalent for $10.6b in Cash Merck Appoints Two Life Sciences Leadership Team Members AMD Commits up to £2b to Accelerate AI in UK » More News! » Submit your News! Upcoming Events European Spatial Computing Healthcare Summit 2026 Leipzig EUROMAR … holm (NLSDays 2026) BIO-Europe 2026 Cologne (Köln) » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Merck Healthcare Appoints Head of Global Commercial Strategy Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Coult … ion Appoints Fred Chereau as Chief Executive Officer » More News! » Submit your News! Financings & Acquisitions Merck KGaA to Acquire Bio-Techne for $11.3b (€9.9b) RQ Biotechnology Closes $115m (£85.5m) Series A Financing GSK to Acquire Nuvalent for $10.6b in Cash Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Up … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Bonito Bi
TRIMTECH Therapeutics - Cambridge Innovation Capital Investors Companies TRIMTECH Therapeutics Defeating CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates Spotlight TRIMTECH Therapeutics is creating a differentiated portfolio of potent, highly specific degraders, known as TRIMTACs™ and TRIMGLUEs™, that selectively target the removal of toxic proteins for the treatment of intractable CNS and inflammatory disorder. The approach is based on pioneering research that elucidated the function and mechanism of action of TRIM21, an underexploited but wid … rst Name Last Name Company Name (Required) Email (Required) Consent By clicking submit below, you consent to allow Cambridge Innovation Capital Limited and its subsidiaries, being Cambridge Innovation Capital Manager Limited and any future subsidiaries of either party, to store and process the personal information submitted above to provide you the content requested. Phone This field is for validation purposes and should be left unchanged. PRI supports its international netwo
TRIMTECH Therapeutics raises $47 million in seed funding to advance its TRIMTAC and TRIMGLUE targeted protein degradation portfolio | BIA Skip to content Influencing policy Business environment Finance and tax IP and tech transfer Regulation Skills and talent Manufacturing Medicines Access to medicines Cell and gene therapy Antimicrobial Resistance Use of animals in research Critical technologies Biosolutions Engineering Biology TechBio Genomics mRNA Growing the sector Skills, talent and people Sector jobs Resources Future talent Diversity and inclusion Invest in biotech Women in Biotech Devel … our company BioStart: for early-stage entrepreneurs Search sector opportunities Submit a sector opportunity Innovation Map Become a member BIA Membership directory Member benefits Your guide to navigating the BIA website Join BIA member community Save with Business Solutions Join BIA Interested in membership? Enquire about joining BIA News and insights Resources Member news Submit member news Press releases Media centre Sign up to Newscast Blogs Blog guidelines Reports BIA in … lines Reports BIA international Events BIA Events BioSolutions UK Sector events Submit sector events London Life Sciences Week Supporting BIA events Event FAQs About What is biotech? Meet the team Our board Articles of Association Charity partnership Our charity partnerships Careers Our supporters Login/Register Join BIA You are here: BioIndustry Association News and insights Resources TRIMTECH Therapeutics raises $47 million in seed funding to advance its TRIMTAC and TRIMGLU … supporting innovation investment Blog 9 June 2026 Harness Therapeutics awarded grant from The Michael J. Fox Foundation for Parkinson’s Research Grant awarded through the Parkinson's Disease Therapeutics Pipeline Program to support advancement of Harness' new programme targeting GCase and LIMP2 for Parkinson's disease. Member news Influencing policy Growing the sector Become a member Member benefits Join BIA News and insights Sign up to Newscast BIA Events Privacy Policy The
BioMed Realty and Babraham Research Campus Ltd Complete Lease-Up of Newest Building at Babraham Research Campus, with TRIMTECH Therapeutics and Tagomics - BioMed Realty Skip to content TENANT PORTAL LOGIN CONTACT US Our Properties Explore Properties Velocity Labs Tenant Experience Overview Discover Here Events Amenities Tenant Portal Company About BioMed Realty The BioMed Realty Advantage Leadership Careers News Contact Us Stewardship Overview People Planet Progress Our Properties Explore Properties Velocity Labs Tenant Experience Overview Discover Here Events Amenities Tenant Portal Company A … e of the Innovate UK ICURe Programme, the Royal Society of Edinburgh Enterprise Fellowship Programme, and the Cambridge-based venture-building programme Start Codon, and is backed by a leading investor syndicate including IQ Capital, Calculus Capital, Illumina Ventures, Agilent Ventures, and Mercia. To learn more, visit https://tagomics.com/ . More News In The News Omakase World Market Opens, Bringing an Elevated Culinary Destination to BioMed Realty’s Gateway of Pacifi
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
TRIMTECH Therapeutics Secures $47M in Seed Funding | Zyme Communications posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you ag … rt Wood 4d Report this comment Great to see UK Biotech raising significantly to fund exciting science and drug development with novel TPD approaches as well! Like Reply 5 Reactions 6 Reactions See more comments To view or add a comment, sign in More Relevant Posts Nadiya Ishnazarova 4d Report this post Excited to partner with the TRIMTECH Therapeutics Limited team on this exciting journey! TRIMTECH’s approach to selectively degrading toxic protein aggregates has the
TRIMTECH Therapeutics raises $31M seed funding - European Pharmaceutical Manufacturer Skip to main content Search Talk to us | Media Portfolio | Latest Issue | My Account linkedin RSS Home Pharma Manufacturing News + Latest Pharmaceutical Manufacturing News Manufacturing News Packaging News Sustainability News Logistics & Distribution News Drug Delivery News Biopharma News Digital Health in Pharma News Regulatory News Finance & Investment News Pharmaceutical Insights + Latest Pharmaceutical Insights Manufacturing Insights Packaging Insights Sustainability Insights Logistics & Distr … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. The investment will support further development of the Company’s growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader
TRIMTECH Therapeutics Appoints Alison Lawton as Chair of Board | Business Weekly newspaper posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … , with Cambridge Innovation Capital and SV Health Investors' Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther . Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, the company has demonstrated its ‘TRIMTAC’ degraders can recapitulate degradation seen with other modalities (vectors and antibodies) whilst leaving the functional monomeric form of the target protein intact and ab … Bioscience Enterprise from University of Cambridge where she was awarded a full scholarship by Cambridge Trust. Prior to joining Imunopharm, she served in senior roles at leading biopharmaceutical companies. With extensive experience in high-value therapeutic areas including oncology, vaccines, immunology and ophthalmology, Ms. Fu has profound practical expertise and industry influence in cell and gene therapy (CGT), innovative payment models, and cross-enterprise commercial
Trimtech closes $31m to advance CNS therapeutics pipeline Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media … cal Trials East Coast 2027 Buy Reports Newsletters PT News Trimtech closes seed fund round to advance CNS therapeutics pipeline SV Health Investors' Dementia Discovery Fund and Cambridge Innovation Capital spearheaded the funding round. March 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The company’s pipeline concentrates on creating treatments for diseases such as Alzheimer’s and Huntington’s. Credit: Art_Photo/Shutterstock. Trimte … ate-selective degrader molecules. SV Health Investors’ Dementia Discovery Fund (DDF) and Cambridge Innovation Capital (CIC) spearheaded the funding round, with contributions from M Ventures and Pfizer Ventures. Go deeper with GlobalData Reports NPVM: Deciphera Pharmaceuticals Inc's Vimseltinib Reports NPVM: Neurocrine Biosciences Inc's NBI-1065845 Go deeper with GlobalData The gold standard of business intelligence. Find out more Discover B2B Marketing That Performs Com
TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio – 24/7 BIOPHARMA Skip to content TWENTYFOURSEVENBIOPHARMA x linkedin youtube email TWENTYFOURSEVENBIOPHARMA HOME LIFE SCIENCES VIDEOS PODCASTS PHOTO LIBRARY ADVERTISE ABOUT US SUBSCRIBE Life Sciences TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio 23rd June 2026 TRIMTECH Therapeutics, a biotechnology comp
EU-Startups - TRIMTECH Therapeutics Limited, a... Facebook Log In EU-Startups's Post EU-Startups 4d · Shared with Public TRIMTECH Therapeutics Limited, a Cambridge-based BioTech company developing new treatments for neurodegenerative diseases, has raised an additional €12 million in Seed funding The financing was led by Johnson & Johnson’s corporate venture capital organisation, Johnson & Johnson Innovation – JJDC, Inc., and BGF, who join existing investors. This brings the total for the round to €41 million – following a previous raise. Dr. Nicki Thompson, CEO, TRIMTECH Therapeut
Trimtech Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 Jul 2025 Trimtech Therapeutics Ltd. Holding Company | 2023 | United Kingdom | trimtechtherapeutics.com Holding Company | 2023 | United Kingdom | trimtechtherapeutics.com Last update 08 Jul 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Trimtech Therapeutics Ltd. Login to view more data 0 Patents (Medical) associated with Trimtech Ther … Mar 2025 · www.fiercebiotech.com British investment firm secures $250M to help fund development of new dementia therapeutics This second iteration of the Dementia Discovery Fund has already made four investments, with beneficiaries comprising the U.S.-based Montara Therapeutics, Sudo Biosciences and Violet Therapeutics as well as the U.K.-based Trimtech Therapeutics.\n British investment firm SV Health Investors has secured $250 million to go toward the development of first- … rd the development of first-in-class therapeutics for dementia, the second such fund the venture capitalists have put together.The final push past the finish line came from British Patient Capital, a commercial subsidiary of the British Business Bank, which made a 25 million pound sterling ($32.4 million) commitment to the fund on March 20.This second iteration of the Dementia Discovery Fund will build on the past decade of research progress to support the development of new … , said in the release. SV\'s DDF-2 will continue the strategy of the first fund “to invest in, create and scale the best U.K. and international biotech companies that develop breakthrough, high-impact treatments in this critical field,\" Jung added. Since its 2015 founding, DDF funding has helped 11 assets enter the clinic, according to the release.DDF-2 has already made four investments, according to the fund’s website. Beneficiaries comprise the U.S.-based Montara … 1 PROTACs 06 Mar 2025 · www.pharmaceutical-technology.com Trimtech closes seed fund round to advance CNS therapeutics pipeline The company’s pipeline concentrates on creating treatments for diseases such as Alzheimer’s and Huntington’s. Credit: Art_Photo/Shutterstock. Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advanc
Cambridge Innovation Capital co-leads $31M seed financing for TRIMTECH Therapeutics to advance neurodegenerative disease treatments - Cambridge Innovation Capital Investors Back to news & insights Cambridge Innovation Capital co-leads $31M seed financing for TRIMTECH Therapeutics to advance neurodegenerative disease treatments Back to insights 5 Mar 2025 Cambridge Innovation Capital (CIC), a leading investor in life sciences and deep tech companies, today announced its role as a co-lead investor in TRIMTECH Therapeutics’ $31 million (£25 million) seed funding round. The financing … was oversubscribed, was also co-led by SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. TRIMTECH Therapeutics , a biotech company pioneering targeted protein degradation (TPD) for neurodegenerative disease treatment, is developing a pipeline of potent, CNS-penetrant therapeutics based on it … rst Name Last Name Company Name (Required) Email (Required) Consent By clicking submit below, you consent to allow Cambridge Innovation Capital Limited and its subsidiaries, being Cambridge Innovation Capital Manager Limited and any future subsidiaries of either party, to store and process the personal information submitted above to provide you the content requested. Comments This field is for validation purposes and should be left unchanged. PRI supports its international ne
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation – Cambridge Enterprise Skip to content Study at Cambridge About the University Research at Cambridge Services Connecting Cambridge Innovation Academic Consultancy Services Pioneering Research Innovations Venture Building & Investment About Who we are Our team Our performance Careers The Cambridge Ecosystem Beyond the University Partnerships and collaboration FAQs Stories Events Publications Contact Search Search Menu News TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein d … Cambridge Innovation Capital (CIC) and SV Health Investors ’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company , MP Healthcare Venture Management (MPH) , Cambridge Enterprise Ventures , and Start Codon. The investment will support further development of the Company’s growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecule … and beyond.” Laurence Barker, Partner, SV Health Investors’ Dementia Discovery Fund “CIC is proud to have been part of the creation of TRIMTECH and co-led this financing round. With over 55 million people affected by Alzheimer’s and millions more battling other neurodegenerative disorders, this groundbreaking innovation has the potential to transform the course of treatment for these patients .” Michael Anstey, Partner, Cambridge Innovation Capital Image credits: TRIMTECH La
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
TRIMTECH extends seed round to $47M for protein degradation drugs - European Biotechnology Magazine ADVERTISEMENT Stay up to date every week with the european biotechnology newsletter. ✕ Instagram This field is for validation purposes and should be left unchanged. Email (Required) This field is hidden when viewing the form EBcom NL confirm list This field is hidden when viewing the form Consent I agree to the privacy policy. Stay up to date every week with the european biotechnology newsletter. Log in here to read the desired article. Company This field is for validation purposes and sh … . They join existing investors Cambridge Innovation Capital, Dementia Discovery Fund, M Ventures, Pfizer Ventures, Eli Lilly and Company, MP Healthcare Venture Management, Cambridge Enterprise Ventures and Start Codon. How it works: TRIMTECH is building drug candidates based on TRIM21, an E3 ligase involved in protein degradation. The company says its TRIMTAC and TRIMGLUE platforms can selectively degrade toxic protein aggregates and oligomers while leaving the functional mon … ity of Cambridge, alongside Cambridge Innovation Capital and Dementia Discovery Fund. The company previously announced a $31 million seed round in 2025. Yes, but: TRIMTECH has not disclosed a lead indication, lead target, development timeline or when it expects to enter the clinic. What we’re watching: Most targeted protein degradation companies have focused first on oncology or immunology, where targets, biomarkers and clinical readouts are usually more straightforward, but
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases - SV Health Investors Strategy Therapeutics Healthcare Growth Medtech People Portfolio News Contact Investors SV8 Biotech Fund SV7+ Growth Fund Dementia Discovery Fund-2 SV Biotech Crossover Opportunities Fund SV7 Impact Medicine Fund SV7 Growth Fund Dementia Discovery Fund-1 SV Life Sciences Funds 5-6 SV Fund IV Continuation Fund SV Life Sciences Funds 3-4 TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for … led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund with M Ventures and Pfizer Ventures joining Investment will support further development of CNS penetrant therapeutics based on the Company’s TRIMTAC TM aggregate-selective degraders Cambridge, UK, 05 March 2025: TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. The investment will support further development of the Company’s growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules k … e pipeline. ” Laurence Barker, Partner, SV Health Investors’ Dementia Discovery Fund, said: “ The team at DDF is thrilled to co-lead the creation of TRIMTECH to advance its TRIMTAC platform, which harnesses TRIM21’s unique ability to degrade aggregated proteins while preserving functional monomers. While targeted protein degradation has revolutionized drug discovery, effective clearance of protein aggregates remains a major challenge. TRIMTECH’s differentiated approach direct … ow on X at @CIC_vc and LinkedIn . About SV Health Investors’ Dementia Discovery Fund SV Health Investors’ Dementia Discovery Fund (DDF) is the world’s largest family of specialized venture capital funds that invests exclusively in companies developing or enabling novel therapeutics for dementia. Dementias including Alzheimer’s Disease are arguabl
TRIMTECH Therapeutics Secures $14M in Seed Funding | TRIMTECH Therapeutics Limited posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … am proud to step into the role as CIO of Rhenman & Partners’ newly launched fund, Rhenman Healthcare Next Generation L/S. The strategy is a long/short equity fund, focused on the next generation of healthcare innovators, in micro-, small- and mid-cap companies across biotech, medtech, pharma and services. The fund is initially available to professional investors in select European countries. 211 32 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comm … as in 2024. This exit, completed in conjunction with the 5th anniversary of the fund, marks a major positive milestone for the company, for the fund and for our Limited Partners. Mérieux Equity Partners will remain a shareholder of Swixx Biopharma, continuing to support the company and its teams in the next phase of growth. 👉 https://shorturl.at/pnjZ8 Mérieux Equity Partners Announces the Exit of a Majority of its Stake in Swixx Biopharma Merieux Partners News https://merieu … Financing included participation from new investors including a leading mutual fund, Blackstone Multi-Asset Investing, accounts advised by T. Rowe Price Investment Management, Inc., a leading life sciences fund, Vivo Capital , Affinity Asset Advisors , ADAR1 Capital Management , and existing investors including OrbiMed , SR One Capital Management , Foresite Capital , Surveyor Capital (a Citadel company), Longwood Fund , New Enterprise Associates (NEA) , Deep Track Capital, S
TRIMTECH raises $47m for protein degradation portfolio - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodies M
About - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu About Our mission is to deliver first-in-class medicines to address the critical need for cost-effective, disease-modifying treatments for neurodegeneration that can reach broad patient populations. Our Science and Therapeutic Focus We are developing a pipeline of potent small molecule heterobifunctional TRIMTAC ® and TRIMGLUE ® degraders that harness the innate properties of TRIM21, a novel E3 ligase that is expressed in most tissues. Our therapeutics poten
Scientific Advisory Board - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu Our Team Scientific Advisory Board Professor Alessio Ciulli FRS FRSE FRSC Chair of SAB Professor Alessio Ciulli FRS FRSE FRSC Chair of SAB Professor Alessio Ciulli is renowned for his pioneering work in the field of targeting protein-protein interactions and targeted protein degradation (TPD), a cutting-edge approach in drug discovery that harnesses the cell's natural disposal machinery to eliminate disease-causing proteins. This new moda … velop novel, more effective therapies, particularly through the development and application of molecules known as PROTACs (Proteolysis Targeting Chimeras) and molecular glues. He is best known for contributions to the design of the first drug-like ligands for the von Hippel-Lindau (VHL) E3 ligase, today widely used in bifunctional molecules known as proteolysis-targeting chimeras (PROTACs) with at least four VHL-based PROTACs in clinical trials today. His laboratory solved th
TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025 - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu TRIMTECH Therapeutics named as one of Fierce Biotech’s ‘Fierce 15’ for 2025 22 September 2025 Fierce 15 highlights pre-commercial biotech companies driving the next generation of therapies for patients worldwide Cambridge, UK, 22 September 2025: TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates to combat neurode … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with participation from Pfizer Ventures, M-Ventures, Eli Lilly, and MPH. The team was later delighted when co-founder Dr Leo James was elected as a Fellow of the Royal Society (FRS), one of the highest honours for a UK scientist. In September the Company announced the first two members of its Scientific Advisory Board, prominent targeted protein degradation experts Prof. Alessio Ciulli … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther. TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In March 2025 the Company announced $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP
Board - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu Our Team Board Alison Lawton Independent Chair Alison Lawton Independent Chair Alison Lawton is an executive leader with over 35 years of experience in the biopharma industry. She was president and CEO of Kaleido Biosciences (KLDO) where she led its IPO, and prior to that chief operating officer of Aura Biosciences (AURA). Ms. Lawton spent more than 20 years in various positions of increasing responsibility at Genzyme, and subsequently at Sanofi (following t … Laurence is a Partner at SV Health Investors focussed on the Dementia Discovery Fund (DDF). With over 20 years of venture, biotech and pharma experience, Laurence has supported the funding and formation of numerous DDF companies developing transformational new medicines for dementia. He joined SV in 2016 having played an active role in setting up the DDF. Prior to SV, Laurence was Head of Investment Management in Worldwide Business Development at GSK where he was responsible … ty. She is a member of the advisory board for Connecticut Bioscience Innovation Fund and has multiple roles on non-profit boards in the community. Marie-Claire received a B.Pharm.Hons. degree in Pharmacy and a Ph.D. in Physiology & Pharmacology from the University of Nottingham U.K. She is a member of the Royal College of Pharmacy. Hakan Goker, PhD Non-Executive Director Hakan Goker, PhD Non-Executive Director Hakan is Managing Director of M Ventures and heads the Biotechnolo
News - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu Press Releases TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio 23 June 2026 TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed f … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. Read more https://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svg 0 0 webmaster https://trimtechtherapeutics.com/wp-content/uploads/2025/02/TRIMTECHTx_Logo_RGB.svg webmas
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases 5 March 2025 Oversubscribed financing led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund with M Ventures and Pfizer Ventures joining Investment will suppo … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF), with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. The investment will support further development of the Company’s growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules k … he pipeline.” Laurence Barker, Partner, SV Health Investors’ Dementia Discovery Fund, said: “The team at DDF is thrilled to co-lead the creation of TRIMTECH to advance its TRIMTAC platform, which harnesses TRIM21’s unique ability to degrade aggregated proteins while preserving functional monomers. While targeted protein degradation has revolutionized drug discovery, effective clearance of protein aggregates remains a major challenge. TRIMTECH’s differentiated approach directl
Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates About We are creating a differentiated portfolio of potent, highly specific degraders, known as TRIMTACs ® and TRIMGLUEs ® , that selectively target the removal of toxic proteins for the treatment of intractable CNS and inflammatory disorders. Learn more Team Led by a team of world-renowned scientists, experienced entrepreneurs and pharma and bio
TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio - Trimtech Therapeutics About Team Board Scientific Advisory Board Science News Press Releases In the News Events Contact Menu Menu TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio 23 June 2026 Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), … Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther. TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In 2025, the Company announced its $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP